Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
about
Anti-endotoxin vaccines: back to the futurePassive immunity in prevention and treatment of infectious diseasesHuman CAP18: a novel antimicrobial lipopolysaccharide-binding proteinTowards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnectReducing mortality in sepsis: new directionsA murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharideUse of synthetic antigens to determine the epitope specificities of monoclonal antibodies against the 3-deoxy-D-manno-octulosonate region of bacterial lipopolysaccharideThe mortality of hospital-acquired bloodstream infections: need for a new vital statisticIntensive care.The role of the E2F1 transcription factor in the innate immune response to systemic LPS.Evolution of the ferric enterobactin receptor in gram-negative bacteriaPrevention of fever and gram negative infection after open heart surgery by antiendotoxin.Monoclonal antibodies to endotoxin in the management of sepsis.A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharidesAnti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.Critical appraisal of therapeutic interventions in the intensive care unit: human monoclonal antibody treatment in sepsis. Journal Club of the Hamilton Regional Critical Care Group.Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria.Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.Anti-inflammatory therapies in sepsis and septic shock.Prevention of clinical coliform mastitis in dairy cows by a mutant Escherichia coli vaccine.Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteriaTherapies for sepsis. Emerging therapies for sepsis and septic shockNitric oxide and septic shock. From bench to bedsideNosocomial pneumonia in patients in intensive care units.New developments in the treatment of gram-negative bacteremia.Neutralization of bacterial lipopolysaccharides by human plasmaEfficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsisLipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains.Endotoxemia: methods of detection and clinical correlatesCrystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution.An anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge with endotoxin.Influence of polyclonal immunoglobulins on the polymorphonuclear leukocyte response to lipopolysaccharide of Salmonella enteritidis as measured with luminol-enhanced chemiluminescence.Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides.Administration in vivo of recombinant interleukin 2 protects mice against septic death.Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding.Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniaeModulation of endotoxin lethality in mice by hydrazine sulfate
P2860
Q22305428-9F0D01CC-D908-4032-AD73-16DBCB0DE67BQ24550699-CF952356-21E0-4431-9C1C-EA4BB1ECE79FQ24682905-186CC4A6-61D6-4D39-A311-51AC10437100Q26996658-418872C5-1D5C-40FC-A202-6DE10A7F6EFEQ28195791-F2E90C23-9AFB-4DDD-A11F-5DA6A1B8D934Q28337542-2B336A54-6BB0-44D7-9FC6-1AB9BFBCABC8Q28337638-747D475B-C35E-4742-A85F-A4D06ED2AF43Q30443206-2CA6D5C2-61EB-43BB-A754-BB8580CF9397Q30493400-F0AA9B11-6A4D-4C71-8CBA-5D846F1480B4Q30666153-413A0F0C-7FD4-4CC4-90E4-98597844C42AQ33266872-2C845E32-BDE2-4C4A-83E3-EB9F36F81042Q33603717-DCD05C31-9670-490E-ADE5-65F050CB169FQ33606835-9057B646-74C2-4A1F-9EB1-F9EE2AB7763BQ33608312-4123DE98-1585-46DE-A258-B2C8352C6ED6Q33631108-05183F5F-89E2-4782-960F-E637D76D36CCQ33814903-38C485BE-D942-4003-B640-52F95C79F3F6Q33836853-87F5C494-FC6A-4058-9AA3-2D0FB389D28CQ33857147-C085466A-8181-4BF2-BDAD-FD8D06455880Q33976703-453AABDA-1C8A-4401-8F38-53CEAE3A4100Q34004972-16634EB7-146A-4D96-8E46-494F87F475E6Q34074976-EE50239E-2ECF-4757-9957-6440452FFB1FQ34081376-389066D0-674D-4385-9C75-98B3C15946EEQ34172977-DE60ED06-C6A7-44B3-A5C9-7EF81DBA5711Q34185446-BDE6B784-5CD5-4488-B581-F95A74C87BBBQ34187914-D2CDB793-AB60-4F9F-87A2-8B85C72624C4Q34193009-CC9491E0-3603-45FF-AC5F-6814452CB9E4Q34193370-1804D202-1D5A-4D2D-BBF3-8A28A7D4E1B8Q34194710-8DE128F6-D750-4F79-94F9-48E09E5B3E2BQ34198040-E9121A56-FC45-425C-B1B5-8B5BF30FAC10Q34289818-8CA75400-5947-4869-A114-36C971455257Q34300796-AECCF81A-908B-4D30-9401-800995AEB066Q34345762-B9772F00-2C8D-4681-8717-98D9D397DF85Q34537934-0947EF35-0024-40ED-A3D0-AE428F93FC49Q34540420-9E4A5CD8-AC8D-4768-A8DB-6B6AFF933A0AQ34572019-91CBE660-4B73-4909-B3FF-3AA8A52C46F4Q34576288-B48D02D6-7A3D-44E1-BB60-8107546BC1AEQ34577529-6B65EC81-FE6A-46D2-8770-F372B0DF2E57Q34660095-195427ED-EC50-4AF8-876D-8C2237FC3F50Q35103543-FF253386-AC68-4361-A104-D1E431DC67F9Q35111435-CC2EB6CD-7274-45D9-9AA7-1C5F12D64B6F
P2860
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh-hant
name
Treatment of gram-negative bac ...... to a mutant Escherichia coli.
@en
Treatment of gram-negative bac ...... to a mutant Escherichia coli.
@nl
type
label
Treatment of gram-negative bac ...... to a mutant Escherichia coli.
@en
Treatment of gram-negative bac ...... to a mutant Escherichia coli.
@nl
prefLabel
Treatment of gram-negative bac ...... to a mutant Escherichia coli.
@en
Treatment of gram-negative bac ...... to a mutant Escherichia coli.
@nl
P2093
P1476
Treatment of gram-negative bac ...... to a mutant Escherichia coli.
@en
P2093
Glauser MP
McCutchan JA
Ziegler EJ
P304
P356
10.1056/NEJM198211113072001
P407
P577
1982-11-01T00:00:00Z